Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2) on its cells.

Atom Bioscience focused on innovative therapies for metabolic and inflammatory conditions, has initiated patient enrollment across the United States for a Phase 2b/3 study of ABP-671.

April 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Endeavor BioMedicines has successfully secured $132.5 million in an oversubscribed Series C funding round to progress their groundbreaking medical pipeline.

BCVA stands for Best Corrected Visual Acuity, which is a key indicator commonly used in ophthalmic clinical trials to evaluate a patient's visual acuity.

Arrowhead Pharmaceuticals has started a Phase 1/2a trial for ARO-CFB aimed at treating kidney diseases caused by complement system dysfunctions.

April 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The FDA has approved Novartis's radioligand treatment, Lutathera®, as the initial specific drug for young patients with neuroendocrine tumors of the gastroenteropancreatic area.

The Therapeutic Index (TI) is an important parameter in assessing the safety of drugs. It is used to measure the relationship between the safety and effectiveness of a drug.

European Commission approves Astellas' XTANDI™ (Enzalutamide) for expanded use in recurrent early-stage prostate cancer treatment.

CSL Vifor and Travere Therapeutics Report European Commission's Approval of FILSPARI® (sparsentan) for IgA Nephropathy Treatment.

OncoC4 Reveals FDA Approval for Investigational New Drug Application of Its Unique SIGLEC 10 Immune Checkpoint Blocker, ONC-841, Targeting Solid Tumors.